Hugo Fry, Topas Therapeutics CEO

May 5, 2025 03:01 AM EDTUpdated 06:18 AM

Exclusive: Topas claims success in early test of 'immune tolerance' therapy for celiac disease

Ryan Cross

Senior Science Correspondent

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Who pays the most in biopharma? We analyzed median pay at 177 companies

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

Kidney health biotech emerges with $54M to follow in Vertex’s footsteps

Ultragenyx, Mereo’s bone disease drug fails second interim analysis, stocks plummet

Swiss and German radiopharma biotech Nuclidium collects $99M Series B

sponsored

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases